E-Cigarette or Vaping Product Use–associated Lung Injury: Developing a Research Agenda. An NIH Workshop Report
Laura E. Crotty Alexander, Lorraine B. Ware, Carolyn S. Calfee, Sean J. Callahan, Thomas Eissenberg, Carol Farver, Maciej Ł. Goniewicz, Ilona Jaspers, Farrah Kheradmand, Talmadge E. King, Nuala J. Meyer, Vladimir B. Mikheev, Peter G. Shields, Alan Shihadeh, Robert M. Strongin, Robert Tarran
Abstract
The NHLBI convened a working group on October 23, 2019, to identify the most relevant and urgent research priorities and prevailing challenges in e-cigarette or vaping product use-associated lung injury (EVALI). Experts across multiple disciplines discussed the complexities of the EVALI outbreak, identified research priorities, and recommended strategies to address most effectively its causal factors and improve diagnosis, treatment, and prevention of this disease. Many research priorities were identified, including the need to create national and international registries of patients with EVALI, to track accurately those affected and assess outcomes. The group concluded that biospecimens from subjects with EVALI are urgently needed to help define EVALI pathogenesis and that vaping has disease risks that are disparate from smoking, with the occurrence of EVALI highlighting the importance of broadening e-cigarette research beyond comparators to smoking-related diseases.